


Luminex

xMAP[®]CONNECT

SHARING MULTIPLEX SOLUTIONS



BOSTON

September 18, 2018

SCHEDULE

8:30 a.m. - 9:30 a.m.	Light Breakfast & Registration
9:30 a.m. - 9:35 a.m.	Welcome Remarks Tom DesRoches, Vice President, Licensed Technologies Group, Luminex Corporation
9:35 a.m. - 10:05 a.m.	The Universal Attachment of Peptide Receptors to xMAP® Microspheres for Multiplexed Biodetection Assays Matthew Coppock, Chemist, U.S. Army Research Lab
10:05 a.m. - 10:35 a.m.	Perils and Pitfalls in Developing a Clinical Assay Hideki Furuya, Assistant Professor, University of Hawaii Cancer Center, University of Hawaii at Manoa
10:35 a.m. - 10:45 a.m.	Bio-Plex Pro™ Human Cytokine Screening Panel 48-plex: SMARTS Design Delivers Actionable Results Amy Hendricksen, Bio-Plex Marketing Manager, Bio-Rad Laboratories
10:45 a.m. - 11:15 a.m.	Break Exhibits & Posters Open
11:15 a.m. - 11:45 a.m.	Use of the Luminex Platform vs. Other Approaches to Interrogate Epigenetic Targets Michael-Christopher Keogh, Chief Scientific Officer, EpiCypher
11:45 a.m. - 12:15 p.m.	Multiplexed Measurement of In-vivo Titrated Human Cytokine Cocktails and Endogenously Produced Human Cytokines in Humanized Mice Wilfredo Garcia Beltran, Post-Doctoral Research/Clinical Fellow, Ragon Institute of MGH, MIT, and Harvard
12:15 p.m. - 12:25 p.m.	QuantiGene™ Assays for Telomere Length Jim Giron, Senior Field Application Scientist, Thermo Fisher Scientific
12:25 p.m. - 1:30 p.m.	Lunch
1:30 p.m. - 1:40 p.m.	Custom MILLIPLEX® Assay Development Case Study: Custom-Made MILLIPLEX® MAP Assays Aid Unique Toxicity Tests Mike Godeny, Product Manager, Immunoassay Platform Solutions, MilliporeSigma
1:40 p.m. - 2:10 p.m.	Use of xMAP Technology to Quantify Gene Expression and Address Potential Cytochrome P450 Inducers Angela Slitt, Associate Professor, Department of Biomedical and Pharmaceutical Sciences, University of Rhode Island College of Pharmacy
2:10 p.m. - 2:40 p.m.	A Multiplexed Immunogenicity Screening Assay for the Development of Flavivirus Vaccines Eric Shaw, Head of Clinical Assay Development, Takeda Vaccines
2:40 p.m. - 2:50 p.m.	The Devil is in the Diluents Alaina Peterson, Immunoassay Specialist, Bio-Techne
2:50 p.m. - 3:15 p.m.	Break Exhibits & Posters Open
3:15 p.m. - 3:45 p.m.	Simultaneous Multiplex Analysis of RNA and Protein Expression in Inflamed CNS Tissues Monica Manglani, Research Scientist, National Institute of Neurological Disorders and Stroke
3:45 p.m. - 4:15 p.m.	xMAP® Protein Conformational Array for Novel and Biosimilar mAB Development Xing Wang, President, Array Bridge
4:15 p.m. - 4:30 p.m.	Closing Remarks Sherry Dunbar, Senior Director, Global Scientific Affairs, Luminex Corporation
4:30 p.m. - 6:00 p.m.	Networking Reception Sauciety Bar *Located on the Lobby Level of The Westin Boston Waterfront Hotel



Speakers

Matthew B. Coppock, PhD

Chemist

U.S. Army Research Lab, Adelphi, MD

Dr. Matthew B. Coppock obtained his B.S. in Chemistry from the University of Richmond in 2007 and received his PhD degree in Chemistry from Penn State University in 2012. He joined the U.S. Army Research Laboratory as an Oak Ridge Associated Universities (ORAU) postdoctoral fellow before becoming a civilian employee in 2015. His research interests include synthetic peptide chemistry, proteomics, spectroscopy, and assay development. He is currently the technical lead for the development and integration of stable, high affinity, and highly selective peptide-based receptors for ruggedized biological assays.

Tom DesRoches

Vice President, Licensed Technologies Group, Luminex Corporation

Tom DesRoches joined Luminex in September of 2010 as Director of Sales, Molecular Diagnostics, Americas. He was promoted to Senior Director, Corporate Accounts and Marketing in January, 2014 and to Vice President, Licensed Technologies Group in May, 2018. Prior to Luminex from 2004 to 2010, Tom was with Roche Diagnostics, where he served as Director, Market Development, leading the Molecular Centers of Excellence program, and then as Corporate Account Director, for Roche and Ventana. Prior to Roche, he held various commercial leadership positions with Abbott Laboratories and Quest Diagnostics dating from 1994 to 2004. Mr. DesRoches holds a B.S. in Marketing Management from the Pamplin College of Business, Virginia Polytechnic Institute & State University.

Sherry Dunbar, PhD, MBA

Senior Director, Global Scientific Affairs, Luminex Corporation

Dr. Dunbar received a B.S. degree in Microbiology and Immunology from the University of Maryland, a PhD in Medical Microbiology and Immunology from the University of South Alabama, College of Medicine, and an MBA from the University of Maryland. She completed her postdoctoral fellowship training in Clinical and Public Health Microbiology at Baylor College of Medicine and was the Laboratory Director of Virus Reference Laboratory in Houston, Texas. Dr. Dunbar joined Luminex as a Senior Scientist in 1999 and served as Senior Director of the Biology Research and Development group for eight years. She is currently the Senior Director of Global Scientific Affairs for Luminex. Dr. Dunbar has developed hundreds of multiplexed assay panels for proteins, nucleic acids, and other biomolecules on the xMAP® Technology platform. She has presented more than 20 abstracts at scientific conferences and has more than 30 publications in peer-reviewed journals.

Hideki Furuya, PhD

Assistant Professor, University of Hawaii Cancer Center

University of Hawaii at Manoa

Dr. Furuya's research program is focused on the identification of urine-based biomarkers for bladder cancer detection and diagnosis as well as assessing the SphK1/S1P, sphingolipids (bioactive lipids), pathway as a strategy for cancer chemoprevention. His research goals are directed toward understanding the basis for cancers and translation of basic research into improving clinical therapeutic outcomes through a personalized and precision medicine approach. His ultimate aim is to develop a biomarker-based diagnostic tool to provide better precision medicines for cancers. He completed his postdoctoral training in Molecular Biology at Medical University of South Carolina, Charleston and his doctorate in Animal Carcinogenesis at Meiji University, Japan.

Wilfredo F. Garcia-Beltran, MD, PhD

Post-Doctoral Research/Clinical Fellow

Ragon Institute of MGH, MIT, and Harvard

Dr. Garcia-Beltran earned his doctoral degree from Harvard University studying the role of natural killer (NK) cells in HIV-1 infection. He also completed his medical degree at Harvard Medical School in 2018 and is currently in the clinical pathology residency program at Massachusetts General Hospital. His postdoctoral research focuses on human immune reconstitution in the humanized bone marrow-liver-thymus (HuBLT) mouse model, demonstrating that innate immune reconstitution is a requirement essential for adaptive immune responses to HIV-1 infection and can be enhanced via AAV-mediated human cytokine delivery.

Michael-Christopher Keogh, PhD

Chief Scientific Officer, EpiCypher

Dr. Keogh earned his doctorate in Molecular Immunology from Imperial College London and completed postdoctoral studies in the Thrombosis Research Institute (London) and with Dr. Steve Buratowski at Harvard Medical School. Before joining EpiCypher, he was a Principal Investigator in the Department of Cell Biology at Albert Einstein College of Medicine. His work has focused on many key oncology research areas including cell-cycle regulation, DNA repair, epigenetics, gene expression, and genetic networks.

Monica Manglani

National Institute of Health

Monica Manglani is currently conducting research under the direction of Dr. Dorian McGavern in the Viral Immunology and Intravital Imaging Section at the National Institute of Neurological Disorders and Stroke (NINDS). She received her undergraduate training at Lafayette College where she studied the role of neuronal migration in the development of epilepsy as well as developmental dyslexia. Her current research at NINDS focuses on disruption of the blood-brain barrier (BBB) during the development of cerebral malaria - a potentially fatal complication associated with *Plasmodium falciparum* infection in humans and *Plasmodium berghei* infection in rodents. For this project, she uses a combination of multiplex platforms and advanced imaging techniques to probe BBB dynamics in vivo and to identify inflammatory factors that contribute to its disruption.

Angela Slitt, PhD

Associate Professor, Department of Biomedical and Pharmaceutical Sciences

University of Rhode Island, College of Pharmacy

Dr. Slitt's research interests focus on how: 1) expression of drug transporters affects chemical (i.e., drug and environmental chemical) disposition and toxicity, 2) nutrition and intake of dietary antioxidants affects the expression of drug transporters, 3) liver disease (i.e., diabetes, cholestasis, and ethanol cirrhosis) affects transporter expression and chemical disposition, and 4) transporter expression affects cholesterol transport and susceptibility to gallstone formation.

Eric Shaw

Head of Vaccine Clinical Assay Development, Takeda Vaccines

As head of clinical assay development and validation for the vaccine business unit, Mr. Shaw is responsible for immunogenicity and cell-based assays including assay development strategy, clinical assay development and validation, and assay regulatory strategy. Before Takeda, he was with Nuron Biotech, Tandem Labs, and Merck. He is an expert in clinical assay development and validation for vaccines and therapeutic biologics as well as immunogenicity testing of biologics, both large molecules and vaccines.

Xing Wang, PhD

President, Array Bridge Inc.

Array Bridge provides products and services that address two important areas in the development of biologics: biosimilar drug comparability analysis and impurity analysis. Before leading Array Bridge, Dr. Wang spent 14 years at Pfizer developing biologics with a focus on bioassay development and process-related impurity analysis.

Thank you to our sponsors!



biotechne®

MILLIPORE
SIGMA

ThermoFisher
S C I E N T I F I C

Map

Meeting Room - Harbor Ballroom

Mezzanine Level

